vs
Side-by-side financial comparison of BioAge Labs, Inc. (BIOA) and Peraso Inc. (PRSO). Click either name above to swap in a different company.
BioAge Labs, Inc. is the larger business by last-quarter revenue ($3.1M vs $2.9M, roughly 1.1× Peraso Inc.). Peraso Inc. runs the higher net margin — -43.3% vs -842.9%, a 799.5% gap on every dollar of revenue.
Altos Labs, Inc. is an American biotechnology research company. Altos Labs' goal is to develop life extension therapies that can halt or reverse the human aging process. Specialized cell therapies based on induced pluripotent stem cells are to be developed for this purpose. Russian-born technology businessman Yuri Milner, along with investors including Jeff Bezos, funded the company in 2021, operations started in 2022.
Peraso Inc. is a semiconductor technology firm specializing in the design and production of high-performance millimeter wave (mmWave) integrated circuits and modules. It delivers 5G and next-generation wireless connectivity solutions for telecom infrastructure, industrial IoT, fixed wireless access and consumer electronics segments, serving customers across North America, Asia Pacific and European markets.
BIOA vs PRSO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.1M | $2.9M |
| Net Profit | $-25.9M | $-1.2M |
| Gross Margin | — | 52.2% |
| Operating Margin | -923.4% | -44.6% |
| Net Margin | -842.9% | -43.3% |
| Revenue YoY | — | -22.0% |
| Net Profit YoY | — | 20.3% |
| EPS (diluted) | $-0.72 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.1M | $2.9M | ||
| Q3 25 | $2.1M | $3.2M | ||
| Q2 25 | $2.4M | $2.2M | ||
| Q1 25 | $1.5M | $3.9M | ||
| Q4 24 | — | $3.7M | ||
| Q3 24 | $0 | $3.8M | ||
| Q2 24 | — | $4.2M | ||
| Q1 24 | — | $2.8M |
| Q4 25 | $-25.9M | $-1.2M | ||
| Q3 25 | $-20.2M | $-1.2M | ||
| Q2 25 | $-21.6M | $-1.8M | ||
| Q1 25 | $-12.9M | $-471.0K | ||
| Q4 24 | — | $-1.6M | ||
| Q3 24 | $-23.4M | $-2.7M | ||
| Q2 24 | — | $-4.4M | ||
| Q1 24 | — | $-2.0M |
| Q4 25 | — | 52.2% | ||
| Q3 25 | — | 56.2% | ||
| Q2 25 | — | 48.3% | ||
| Q1 25 | — | 69.3% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 47.0% | ||
| Q2 24 | — | 55.5% | ||
| Q1 24 | — | 46.4% |
| Q4 25 | -923.4% | -44.6% | ||
| Q3 25 | -1126.6% | -36.8% | ||
| Q2 25 | -1027.0% | -80.0% | ||
| Q1 25 | -1133.4% | -13.3% | ||
| Q4 24 | — | -44.3% | ||
| Q3 24 | — | -70.3% | ||
| Q2 24 | — | -105.6% | ||
| Q1 24 | — | -128.9% |
| Q4 25 | -842.9% | -43.3% | ||
| Q3 25 | -982.0% | -37.4% | ||
| Q2 25 | -894.0% | -82.4% | ||
| Q1 25 | -891.0% | -12.2% | ||
| Q4 24 | — | -42.4% | ||
| Q3 24 | — | -70.6% | ||
| Q2 24 | — | -104.4% | ||
| Q1 24 | — | -72.1% |
| Q4 25 | $-0.72 | $-0.09 | ||
| Q3 25 | $-0.56 | $-0.17 | ||
| Q2 25 | $-0.60 | $-0.31 | ||
| Q1 25 | $-0.36 | $-0.10 | ||
| Q4 24 | — | $0.36 | ||
| Q3 24 | $-6.70 | $-0.98 | ||
| Q2 24 | — | $-1.88 | ||
| Q1 24 | — | $-1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $281.1M | $2.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $272.1M | $4.6M |
| Total Assets | $294.9M | $6.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $281.1M | $2.9M | ||
| Q3 25 | $285.8M | — | ||
| Q2 25 | $297.3M | — | ||
| Q1 25 | $320.5M | — | ||
| Q4 24 | — | $3.3M | ||
| Q3 24 | $334.5M | $1.3M | ||
| Q2 24 | — | $1.9M | ||
| Q1 24 | — | $2.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $7.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.9M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $272.1M | $4.6M | ||
| Q3 25 | $277.5M | $3.6M | ||
| Q2 25 | $294.8M | $3.0M | ||
| Q1 25 | $313.2M | $3.6M | ||
| Q4 24 | — | $3.5M | ||
| Q3 24 | $313.7M | $2.0M | ||
| Q2 24 | — | $3.6M | ||
| Q1 24 | — | $6.7M |
| Q4 25 | $294.9M | $6.1M | ||
| Q3 25 | $305.1M | $6.2M | ||
| Q2 25 | $322.1M | $5.5M | ||
| Q1 25 | $343.8M | $6.7M | ||
| Q4 24 | — | $7.2M | ||
| Q3 24 | $337.4M | $7.2M | ||
| Q2 24 | — | $9.8M | ||
| Q1 24 | — | $11.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.03× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-28.3M | $-1.1M |
| Free Cash FlowOCF − Capex | $-28.4M | — |
| FCF MarginFCF / Revenue | -921.5% | — |
| Capex IntensityCapex / Revenue | 3.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-82.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-28.3M | $-1.1M | ||
| Q3 25 | $-16.0M | $-1.5M | ||
| Q2 25 | $-20.0M | $-2.0M | ||
| Q1 25 | $-17.4M | $-966.0K | ||
| Q4 24 | — | $-687.0K | ||
| Q3 24 | — | $-683.0K | ||
| Q2 24 | — | $-659.0K | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | $-28.4M | — | ||
| Q3 25 | $-16.1M | $-1.6M | ||
| Q2 25 | $-20.1M | — | ||
| Q1 25 | $-17.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -921.5% | — | ||
| Q3 25 | -782.2% | -48.9% | ||
| Q2 25 | -834.5% | — | ||
| Q1 25 | -1226.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 3.6% | — | ||
| Q3 25 | 1.1% | 1.1% | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 29.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIOA
Segment breakdown not available.
PRSO
| Products | $2.8M | 96% |
| Other | $105.0K | 4% |
